The American Heart Association (Association) and the Cardiovascular Research Foundation (CRF) have announced a new alliance to produce joint education programmes, beginning with the organisations’ annual scientific meetings this autumn.

Projected rates of cardiovascular risk factors and disease will increase significantly in the USA by 2060, a study published in the Journal of the American College of Cardiology(JACC) has claimed.

Cardiac surgeons from North America, Europe and Latin America are among the signatories to a multidisciplinary group seeking to address what it describes as a “widening gap” between evidence and guideline recommendations in cardiovascular medicine.

A project to develop genetic therapies to effectively cure cardiomyopathy has been announced as the winner of the British Heart Foundation’s Big Beat Challenge, a £30 million innovation projecttargeting unmet needs in heart disease.

Incentives for the enrolment of patients from socieconomically disadvantaged groups, as well as targets for racial and ethnic minority patients, may be a way to ensure that clinical trials of devices for structural heart disease are more representative of the wider population, attendees of The Structural Heart Summit (TVT 2022, 8–10 June, Chicago, USA) heard.

Cathbot—a joint venture between Robocath and MicroPort—has enrolled the last patient in its clinical study in China. This is the first step towards obtaining approval from China’s National Medical Products Administration (NMPA) for the commercialisation of R-One, the robotic percutaneous coronary intervention (PCI) platform, in the Chinese market.

Preventing coronary obstruction after transcatheter aortic valve implantation (TAVI) becomes increasingly important as the procedure moves into a lower-risk patient population. According to researchers in Europe and Israel, a new device may offer a simple solution to preventing this complication in TAVI patients.

Ancora Heart has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Accucinch ventricular restoration system.

The VenusP-Valve (Venus Medtech) transcatheter pulmonic valve replacement (TPVR) system has been approved by China’s National Medical Products Administration (NMPA) for the treatment of severe pulmonary regurgitation in patients who have undergone a congenital heart defect (CHD) procedure with native right ventricular outflow tract (RVOT).

Patients identified by nuclear stress testing as having severe stress-induced myocardial ischaemia  are likely to benefit from early coronary revascularisation through either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI), while those with mild or no ischaemia are not, according to a new study published in the Journal of the American College of Cardiology (JACC).

Echocardiographers may be at significantly greater risk of exposure to radiation than interventional cardiologists when performing structural heart procedures in the cath lab, new research published in JAMA Network Open suggests.

The Cardiovascular Research Foundation (CRF) and Fogarty Innovation have announced the launch of the TCT MedTech Innovation Forum, a summit dedicated to advances in medtech.